|
Showing 1 - 4 of
4 matches in All Departments
Is the nephrology community facilitating excess cardiovascular
deaths in patients with kidney failure and anemia by treating to a
subnormal hematocrit? Why have clinicians and nephrologists
permitted health insurance companies and the government to decide
when anemia therapy should begin in persons with progressive kidney
failure? Is iron the only variable that can be manipulated to
maximize response to recombinant erythropoietin? Are we using too
much intravenous iron in kidney failure patients, and is oral iron
supplementation worthless in sustaining iron stores during
long-term erythropoietin treatment? When does left ventricular
hypertrophy begin to emerge in patients with progressive renal
disease and is there convincing evidence that anemia is a
significant cause of LVH in this setting? Is darbepoetin alfa, a
new novel, long-acting erythropoietin, really superior to
recombinant erythropoietin? This book is a compilation of
proceedings from a conference in Brooklyn convened to address these
and other controversial and unresolved issues in renal anemia
management.
Is the nephrology community facilitating excess cardiovascular
deaths in patients with kidney failure and anemia by treating to a
subnormal hematocrit? Why have clinicians and nephrologists
permitted health insurance companies and the government to decide
when anemia therapy should begin in persons with progressive kidney
failure? Is iron the only variable that can be manipulated to
maximize response to recombinant erythropoietin? Are we using too
much intravenous iron in kidney failure patients, and is oral iron
supplementation worthless in sustaining iron stores during
long-term erythropoietin treatment? When does left ventricular
hypertrophy begin to emerge in patients with progressive renal
disease and is there convincing evidence that anemia is a
significant cause of LVH in this setting? Is darbepoetin alfa, a
new novel, long-acting erythropoietin, really superior to
recombinant erythropoietin? This book is a compilation of
proceedings from a conference in Brooklyn convened to address these
and other controversial and unresolved issues in renal anemia
management.
Is the increased susceptibility of blacks to kidney failure from
HIV-AIDS explained by biology or socioeconomic variables? Is kidney
failure an early or late complication of HIV infection? Are there
receptors for HIV in kidney tissue and is the kidney a major
reservoir for the virus? Is acute renal failure an inevitable
consequence of drug treatment in HIV disease? Should kidney or
solid organ transplantation be offered to patients with HIV
infection? Can HIV-associated nephrotherapy be prevented or
reversed by drug therapy and has HAART eradicated pediatric HIV
nephrotherapy? What is the level of risk to staff and other
patients in dialysis facilities that treat HIV-infected patients?
These questions and other critical issues are addressed in-depth by
some of the world's leading basic scientists and clinician
researchers in kidney disorders of HIV-AIDS.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.